El papel de los marcadores tumorales en la consulta de urología para el screening, diagnóstico y seguimiento del cáncer de vejiga

Edward, 1998, Bladder cancer. Campbell’s Urology, Seventh Edition, 3, 2.329 Patton, 2002, Bladder cancer, Curr Opin Oncol, 14, 265, 10.1097/00001622-200205000-00003 Pisani, 1993, Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden, Int J Cancer, 55, 891, 10.1002/ijc.2910550604 Nawrocki, 2002, Pharmacotherapy of bladder cancer - practice and prospects, Expert Opin Pharmacother, 3, 671, 10.1517/14656566.3.6.671 Messing, 1990, Hematuria screening for bladder cancer, J Occup Med, 32, 838, 10.1097/00043764-199009000-00016 Zeegers, 2002, A prospective study on active and environmental tobacco smoking and bladder cancer risk, Cancer Causes Control, 13, 83, 10.1023/A:1013954932343 Sankaranarayanan, 2000, Integration of cost-efective early detection programs into the health services of developing countries, Cancer, 89, 475, 10.1002/1097-0142(20000801)89:3<475::AID-CNCR1>3.0.CO;2-8 ACS News Today: Scientistics confirm cancer risk from second-hand smoke increases cancer risk by one-fifth. Artcle date: 2002/07/09 Hemstreet, 2001, Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine, J Natl Cancer Inst, 93, 427, 10.1093/jnci/93.6.427 Wolf, 2001, Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1G3 urothelial bladder carcinomas, Tumor Biol, 22, 328, 10.1159/000050635 Wiener, 1999, Can urine boung diagnostic tests replace cystoscopy in the management of bladder cancer?, J Urol, 159, 1.876, 10.1016/S0022-5347(01)63184-7 Landman, 1998, Sensitivity and specificity of NMP22, telomerase, and BTA in the detection of human bladder cancer, Urology, 52, 398, 10.1016/S0090-4295(98)00219-2 Koshikava, 1989, Difficulties in evaluating urinary specimens after local mitomycin therapy of bladder cancer, Diagn Cytopathol, 5, 117, 10.1002/dc.2840050202 De, 2002, Editorial comment, J Urol, 167, 83, 10.1016/S0022-5347(01)69558-2 Lokeshwar, 2000, Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade, J Urol, 163, 348, 10.1016/S0022-5347(05)68050-0 Lokeshwar, 2002, Letters to the Editor, J Urol, 167, 1.405 Sarosdy, 1997, Improved detection of recurrent bladder cancer using the Bard BTA stat test, Urology, 50, 349, 10.1016/S0090-4295(97)00292-6 Nasuti, 1999, Utility of the BTAstat test kit for bladder cancer screening, Diagn Cytopathol, 21, 27, 10.1002/(SICI)1097-0339(199907)21:1<27::AID-DC8>3.0.CO;2-8 Leyh, 1999, Comparison of BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer, Eur Urol, 35, 52, 10.1159/000019819 Boman, 2002, Four bladder tumor markers have a disppointingly low sensitivity for small size and low grade recurrence, J Urol, 167, 80, 10.1016/S0022-5347(05)65387-6 Oge, 2001, Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer, Int Urol Nephrol, 32, 367, 10.1023/A:1017509418440 Ohtani, 2001, Urinary tumor marker for urothelial cancer, Gan To Kagaku Ryoho, 28, 1.933 Lokeshwar VB, Soloway M.: Current bladder tumor test: does their projected utility fulfill clinical necessity? J Urol 165 (4): 1.067-1.077. Álvarez-Kindelan, 2000, Biología molecular en el cáncer vesical, Actas Urol Esp, 24, 604, 10.1016/S0210-4806(00)72514-9 Bonner, 1993, Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells, Cancer, 72, 2.461, 10.1002/1097-0142(19931015)72:8<2461::AID-CNCR2820720826>3.0.CO;2-C Konety, 2001, Urine based markers of urological malignancy. J Urol 2001; 165 (2): 600-611. 27. VRIESEMA JL, ATSMA F, KIEMENEY LA, PEELEN WP, WITJES JA, SCHALKEN JA.: Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence, Urology, 58, 367, 10.1016/S0090-4295(01)01217-1 Bonner, 1996, Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for bladder cancer, Cancer Epidemiol Biomarkers Prevent, 5, 971 Sánchez-Carbayo, 2001, Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma, Cancer, 92, 2.820, 10.1002/1097-0142(20011201)92:11<2820::AID-CNCR10092>3.0.CO;2-I Sánchez-Carbayo, 2001, Diagnostic performance of the urinary bladder carcinoma antigen ELISA test and a multiparametric DNA/cytokeratin flowcytometry in urine voided samples from patients with bladder carcinoma, Cancer, 92, 2.811, 10.1002/1097-0142(20011201)92:11<2811::AID-CNCR10101>3.0.CO;2-T Pariente, 1997, Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma, J Urol, 158, 338, 10.1016/S0022-5347(01)64473-2 Mady, 2001, Cytoketarins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS, Int J Biol Markers, 16, 130, 10.1177/172460080101600208 Cajulis, 1995, Cytology, flow cytometry, image analysis and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study, Diag Cytopathol, 13, 214, 10.1002/dc.2840130307 Witjes, 1998, Urinary NMP22 and kariometry in the diagnosis and follow up of patients with superficial bladder cancer, Eur Urol, 33, 387, 10.1159/000019621 Yoshida, 1997, Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection exfoliated cancer cells in urine, Cancer, 79, 362, 10.1002/(SICI)1097-0142(19970115)79:2<362::AID-CNCR20>3.0.CO;2-Y Muller, 1998, Comparison of human telomerase activity in urine for diagnosis of bladder cancer, Clin Cancer Res, 4, 1.949 Miyake, 1998, Urinary cytology and competitive reverse transcriptase-polimerase chain reaction analysis of a specific CD44 variant to detect and monitor bladder cancer, J Urol, 160, 2.004, 10.1016/S0022-5347(01)62225-0 Lokeshwar, 1997, Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer, Cancer Res, 57, 773 Pham, 1997, Tumor-derived hyaluronidase: a diagnostic urine marker for highgrade bladder cancer, Cancer Res, 57, 778